Activation of JNK and High Expression Level of CD133 Predict a Poor Response to Sorafenib in Hepatocellular Carcinoma

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2012.145
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients With Hepatocellular Carcinoma

Journal of Hepatology
Hepatology
2017English

Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients With Hepatocellular Carcinoma

Targeted Oncology
Cancer ResearchOncologyPharmacology
2017English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

High Serum Transforming Growth Factor- 1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated With Sorafenib

Clinical Cancer Research
Cancer ResearchOncology
2015English

Aberrant KIF20A Expression Might Independently Predict Poor Overall Survival and Recurrence-Free Survival of Hepatocellular Carcinoma

IUBMB Life
BiochemistryGeneticsClinical BiochemistryCell BiologyMolecular Biology
2018English

Identification of the Β-Catenin/JNK/Prothymosin-Alpha Axis as a Novel Target of Sorafenib in Hepatocellular Carcinoma Cells

Oncotarget
Oncology
2015English

Cytotoxicity of Sorafenib in Human Hepatocellular Carcinoma Cells

Al-Azhar Journal of Pharmaceutical Sciences
2015English

Early Changes in Apparent Diffusion Coefficient as an Indicator of Response to Sorafenib in Hepatocellular Carcinoma

Journal of Zhejiang University: Science B
GeneticsPharmacologyMolecular BiologyBiochemistryVeterinaryMedicineToxicologyPharmaceutics
2014English

High Expression of Thymosin Beta 10 Predicts Poor Prognosis for Hepatocellular Carcinoma After Hepatectomy

World Journal of Surgical Oncology
SurgeryOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy